心脏收缩性调节在症状性心力衰竭中与减少的射出分数:系统性审查和单臂元分析
Ricardo F O Suruagy-Motta1, Christian K Fukunaga2, Everton V B da Silva3
1Department of Medicine, Cesmac University Center, Maceió, Brazil.
Journal of cardiovascular electrophysiology
|August 11, 2025
概括
心脏收缩性调制 (CCM) 显著改善了心力衰竭患者的运动能力和生活质量,而心力衰竭患者的减少喷射率 (HFrEF) 不符合CRT的条件. 这种疗法为缓解症状和心脏重塑提供了一个有希望的选择.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭研究研究
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭显著影响发病率和死亡率.
- 许多HFrEF患者尽管接受了最佳的医疗治疗,但仍然存在症状.
- 心脏收缩性调制 (CCM) 为症状高频心经衰竭患者提供了一种新的方法,这些患者具有狭窄的QRS复合体,特别是那些不符合心脏再同步治疗 (CRT) 的患者.
研究的目的:
- 评估CCM治疗在症状HFrEF患者中的功能,结构和生活质量影响.
- 评估CCM对运动能力,NYHA功能类和心力衰竭特定生活质量的影响.
- 分析CCM对心脏重塑的影响,包括左心室喷射率 (LVEF) 和体积.
主要方法:
- 系统审查和单臂元分析遵循PRISMA指南.
- 包括15项研究,其中1658名患者被诊断患有症状的HFrEF.
- 主要结局评估包括6分钟步行测试 (6MWT),峰值氧气消耗 (峰值VO2),NYHA功能类和MLHFQ分数;次要结局包括LVEF,LVESV和LVEDV.
主要成果:
- CCM疗法在6MWT距离 (44.96m增加) 和NYHA功能类 (-0.89变化) 中显著改善.
- 通过MLHFQ测量患者报告的生活质量,显示显著改善 (11.83点下降).
- 观察到显著的积极结构变化,包括LVEF增加5.96%,LVESV (24.17mL) 和LVEDV (18.44mL) 减少.
结论:
- CCM疗法显著提高功能能力,缓解症状,并改善了HFrEF患者的生活质量,这些患者不符合CRT的条件.
- 该疗法还促进有益的心脏重塑,支持其在解决关键治疗缺口方面的作用.
- 进一步的大规模随机试验是有必要的,以证实长期的临床结果,并巩固CCM在HFrEF管理中的地位.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27


